Wednesday, May 12, 2021 11:17:27 PM
Trulieve Cannabis: Analyst Q1 Consensus Estimates
May 12, 2021 4:01 PM
By: Justin Young
https://thedeepdive.ca/trulieve-cannabis-analyst-q1-consensus-estimates/
Trulieve Cannabis (CSE: TRUL) announced that they will be reporting their first quarter financials before market open on March 13th. Analysts have a consensus C$88.08 12-month price target on the company, via a total of 15 analysts, with four analysts having a strong buy rating and the other 11 have buy ratings. The street high comes from Stifel-GMP with a C$118 price target, and the lowest target comes from Cantor Fitzgerald with a C$71 price target.
Twelve analysts have revenue estimates for the first quarter. The mean between all 14 is U$188.78 million; this number has been revised slightly upwards from U$184.33 million at the start of the year. PI Financial currently has the highest revenue estimate with U$201 million, while the lowest comes from Stifel-GMP with a U$185.21 million estimate.
Six analysts has estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 70.75%, with this number being revised upwards from 68.33% at the start of the year. Street high goes to Stifel-GMP with a 72.50% estimate and the lowest sits at 68%.
Onto EBITDA estimates, there are currently 12 analysts who have first quarter EBITDA estimates. The mean is currently U$83.83 million, with this number being similar to what it was at the start of the year. Street high goes to Cantor Fitzgerald with a U$87.40 million EBITDA estimate and the lowest being from Haywood with a U$76.40 million estimate.
Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
May 12, 2021 4:01 PM
By: Justin Young
https://thedeepdive.ca/trulieve-cannabis-analyst-q1-consensus-estimates/
Trulieve Cannabis (CSE: TRUL) announced that they will be reporting their first quarter financials before market open on March 13th. Analysts have a consensus C$88.08 12-month price target on the company, via a total of 15 analysts, with four analysts having a strong buy rating and the other 11 have buy ratings. The street high comes from Stifel-GMP with a C$118 price target, and the lowest target comes from Cantor Fitzgerald with a C$71 price target.
Twelve analysts have revenue estimates for the first quarter. The mean between all 14 is U$188.78 million; this number has been revised slightly upwards from U$184.33 million at the start of the year. PI Financial currently has the highest revenue estimate with U$201 million, while the lowest comes from Stifel-GMP with a U$185.21 million estimate.
Six analysts has estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 70.75%, with this number being revised upwards from 68.33% at the start of the year. Street high goes to Stifel-GMP with a 72.50% estimate and the lowest sits at 68%.
Onto EBITDA estimates, there are currently 12 analysts who have first quarter EBITDA estimates. The mean is currently U$83.83 million, with this number being similar to what it was at the start of the year. Street high goes to Cantor Fitzgerald with a U$87.40 million EBITDA estimate and the lowest being from Haywood with a U$76.40 million estimate.
Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
Recent TCNNF News
- Trulieve to Open Medical Cannabis Dispensary in Boca Raton, Florida • PR Newswire (US) • 04/13/2026 12:00:00 PM
- Trulieve to Open Medical Cannabis Dispensary in Lutz, Florida • PR Newswire (US) • 04/10/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 10:23:52 PM
- Trulieve Announces Executive Automatic Securities Disposition Plan • PR Newswire (US) • 03/17/2026 09:59:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 09:41:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 09:36:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 09:33:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 09:10:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 09:05:15 PM
- Trulieve to Open Medical Cannabis Dispensary in DeLand, Florida • PR Newswire (US) • 03/13/2026 12:00:00 PM
- Trulieve to Open Medical Cannabis Dispensary in Lake Wales, Florida • PR Newswire (US) • 03/11/2026 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 08:10:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 09:32:21 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 11:25:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 11:18:31 AM
- Trulieve Reports Fourth Quarter and Full Year 2025 Results with 60% Gross Margin and Record Cash Flow Generation • PR Newswire (US) • 02/26/2026 11:15:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 09:24:04 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/06/2026 08:33:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2026 01:34:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/17/2025 01:19:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2025 10:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2025 09:59:28 PM
